Molecular genetic investigation of hereditary breast and ovarian cancer patients in the Southern Transdanubian region: widening the mutation spectrum and searching for new pathogenic variants using next-generation methods.
Humans
Female
Retrospective Studies
Genetic Predisposition to Disease
Adult
Middle Aged
Mutation
BRCA2 Protein
/ genetics
Ovarian Neoplasms
/ genetics
BRCA1 Protein
/ genetics
High-Throughput Nucleotide Sequencing
/ methods
Hereditary Breast and Ovarian Cancer Syndrome
/ genetics
Aged
Genetic Testing
/ methods
Breast Neoplasms
/ genetics
Genetic Counseling
Young Adult
Biomarkers, Tumor
/ genetics
Antigens, CD
Cadherins
BRCA1
BRCA2
HBOC
multigene panel testing
new generation sequencing
Journal
Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087
Informations de publication
Date de publication:
2024
2024
Historique:
received:
30
04
2024
accepted:
19
07
2024
medline:
16
8
2024
pubmed:
16
8
2024
entrez:
16
8
2024
Statut:
epublish
Résumé
Hereditary breast and ovarian cancer is a well-known genetic condition, inherited mainly in an autosomal dominant way, which elevates the risk of developing malignancies at a young age in heterozygous carriers. Advances in new generation sequencing have enabled medical professionals to determine whether a patient is harbouring mutations in moderate- or high penetrance susceptibility genes. We conducted a retrospective analysis among 275 patients who underwent genetic counselling and multigene panel testing for hereditary breast and ovarian cancer syndrome in our department. From these patients 74.5% (205/275) were affected by some type of malignancy, while the remaining 25.5% (70/275) had a positive family history of different cancers, suggesting a genetic predisposition. These tests confirmed a genetic variant in 29.8% and 28.6% of these patient groups respectively. The results also mirrored our general knowledge concerning the genetic background of hereditary breast and ovarian cancer, as variants in either one of the
Identifiants
pubmed: 39148954
doi: 10.3389/pore.2024.1611813
pii: 1611813
pmc: PMC11324426
doi:
Substances chimiques
BRCA2 Protein
0
BRCA2 protein, human
0
BRCA1 protein, human
0
BRCA1 Protein
0
Biomarkers, Tumor
0
CDH1 protein, human
0
Antigens, CD
0
Cadherins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1611813Informations de copyright
Copyright © 2024 Baráti, Maász, Mikó, Bércesi, Kalbani, Bene, Kovács, Mangel and Hadzsiev.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.